|Home | About | Journals | Submit | Contact Us | Français|
Conceived and designed the experiments: MAP DMO. Performed the experiments: MAP VWL IO CM. Analyzed the data: MAP CM. Contributed reagents/materials/analysis tools: DMO. Wrote the paper: MAP DMO.
Ivermectin is currently approved for treatment of both clinical and veterinary infections by nematodes, including Onchocerca cervicalis in horses and Onchocerca volvulus in humans. However, ivermectin has never been shown to be effective against bacterial pathogens. Here we show that ivermectin also inhibits infection of epithelial cells by the bacterial pathogen, Chlamydia trachomatis, at doses that could be envisioned clinically for sexually-transmitted or ocular infections by Chlamydia.
Avermectins are macrocyclic lactone derivatives which are produced during fermentation of Streptomyces avermectinius, a species of actinomycete isolated from soil samples in Japan. Eight avermectins are produced by S. avermectinius (A1a, A1b, A2a, A2b, B1a, B1b, B2a, and B2b). The A series molecules contain a 5′-methoxyl group, while the B series contain a 5′-hydroxyl group and have more potent anti-parasitic activity , , . Improved efficacy as a broad-spectrum anti-parasitic was achieved for the B1 compounds by selective hydrogenation utilizing Wilkinson’s catalyst (RhCl(PPh3)3), with the resultant product (22,23-dihydroavermectin B1) being given the name ivermectin . Following considerable success as an anti-helminthic agent in veterinary practice, including use for treatment of Onchocerca cervicalis in horses, ivermectin entered clinical trials for use in humans against Onchocerca volvulus, a nematode which causes onchocerciasis (“river blindness”) . Efficacious use in humans has extended to lymphatic filariasis , head-lice infestation , and scabies . However, avermectins have not been previously described to have anti-bacterial activity .
Here we demonstrate that ivermectin inhibits growth of Chlamydia trachomatis during infection of human cervical epithelial cells, suggesting that avermectins may have previously undescribed anti-bacterial activity against pathogenic obligate intracellular bacteria, potentially via indirect effects on the host-cell.
Chlamydiae are obligate intracellular bacteria which mature through a unique biphasic developmental cycle, infecting as metabolically inert elementary bodies (EBs) and maturing into metabolically active but non-infectious reticulate bodies (RBs), which proliferate before condensing into infectious EBs to complete the cycle , , . C. trachomatis strains, which are the leading cause of bacterial sexually transmitted disease and first cause of preventable blindness , primarily infect mucosal epithelial cells.
Five µM ivermectin added one hour post infection (hpi) significantly inhibited the production of infectious EB (Figure 1A) and chlamydial 16s rRNA accumulation (Figure 1B), as evaluated by harvesting infected HeLa cultures and infecting fresh HeLa monolayers followed by fluorescent microscopy to determine infectious units per mL (IFU/ml, Figure 1A), or by RNA extraction of infected HeLa cultures followed by cDNA synthesis and qPCR for C. trachomatis 16s rRNA (Figure 1B). Treatment with 1 µM ivermectin at 1 hpi modestly decreased the size of inclusions, while inclusions in cells treated with 5 µM ivermectin had significantly reduced dimensions (Figure 2). Treatment with 10 µM ivermectin completely inhibited inclusion development. Of note, 5 µM ivermectin did not reduce the number of cells in which inclusions were apparent, suggesting that the effect of ivermectin was not related to uptake of bacteria into host cells.
To exclude the possibility that ivermectin may be inhibiting infection through an indirect cytotoxic effect on the host cells, we verified that treatment of HeLa cells with up to 10 mM ivermectin for 4 to 24 hours did not cause increased cell death (Figure 3A) or lactate dehydrogenase (LDH) release (Figure 3B).
For use in humans as an anti-helminthic, ivermectin is typically received orally at a dose of 150 µg/kg body weight, and peak plasma concentrations from such dosage reach around 60 nM . Ivermectin has also been used and well-tolerated at 500 µg/kg body weight via topical administration in veterinary applications , which could potentially be an attractive mode of use if it is found to be effective against intracellular bacterial pathogens which primarily infect readily accessible mucosal surfaces. Ivermectin targets glutamate-gated chloride channels in nerve and muscle cells and gamma-aminobutyric acid (GABA) related chloride channels of invertebrates , as well as mammalian GABA receptors .
Ivermectin has also been reported to interact with the purinergic receptor, P2X4 , which can be stimulated by low (micromolar) concentrations of ATP; and we have observed that stimulation of C. trachomatis-infected epithelial cells with micromolar concentrations of ATP leads to chlamydial growth inhibition . However, addition of apyrase (2.5 U/ml) to cells immediately prior to ATP addition prevents ATP-mediated chlamydial growth inhibition (unpublished data), but does not modify the impact of ivermectin on chlamydial growth (1 or 2.5 U/ml apyrase, 5 µM ivermectin, N=3; data not shown). These results suggest that ivermectin does not inhibit infection through P2X4 ligation.
We have here demonstrated that ivermectin inhibits C. trachomatis infection in epithelial cells. While the concentrations of ivermectin necessary for this inhibitory action in vitro are higher than what is achieved distal to absorption sites in current human therapy, topical application may allow therapeutic use of ivermectin against sexually-transmitted infection, or against eye infection with ocular strains of C. trachomatis. Additionally, as the target of this particular activity in human cells has yet to be identified, other avermectins or structurally modified avermectin molecules may have greater potency. As it seems that ivermectin mediates this response through interaction with a host cell target, potential efficacy against other obligate intracellular bacteria or parasites is worthy of exploration.
The epithelial cell line HeLa 229 (American Type Culture Collection, Manassas, VA) was used to model infection with the LGV/L2 strain of C. trachomatis (obtained from Dr. Roger Rank, University of Arkansas, Little Rock, AR). HeLa cells were cultured in a humidified incubator at 37 °C with 5% CO2 in Dulbecco’s modified Eagle medium (DMEM:F-12, Invitrogen) supplemented with 10% heat-inactivated fetal calf serum. Apyrase and Hoechst were purchased from Sigma (St. Louis, MO), and antibodies against the C. trachomatis genus antibodies were from Argene (Sherley, NY).
A concentrated stock of ivermectin (Sigma, St. Louis, MO) was solubilized in ethanol, and dilutions were also prepared in ethanol. Control wells received the same concentration of ethanol (0.2%) as treated wells, which did not influence chlamydial infection relative to control wells without ethanol (data not shown).
HeLa cells growing at 70% confluence in tissue culture plates (Costar) were infected at a multiplicity of infection (MOI) of 1.0, with treatments at the indicated times . Infection was assayed by fluorescence microscopy and qPCR for C. trachomatis 16s rRNA, using protocols and primers previously described . To analyze inclusion size and morphology by fluorescent microscopy, HeLa cells were grown on glass coverslips, and after the indicated experimental conditions were fixed with ice cold methanol for 10 minutes. Cells were stained with C. trachomatis genus antibodies from Argene (North Massapequa, NY) and Hoechst (Sigma), and observed on a widefield fluorescence microscope (Leica, Deerfield, IL).
Statistical analysis was performed using GraphPad Prism version 5.0b for Mac (GraphPad Software, San Diego, CA).